Roche to start a new Phase 3 trial for Elevidysnews2026-04-16T15:35:05+00:00April 16th, 2026|Endpoints News|
Lilly’s obesity pill heads for diabetes filing after heart risk trialnews2026-04-16T11:26:00+00:00April 16th, 2026|Endpoints News|
Freya Biosciences advances microbial treatment for IVF implantation failurenews2026-04-16T07:30:02+00:00April 16th, 2026|Endpoints News|
In vivo autoimmune CAR-T race grows as two RNA startups enter the clinicnews2026-04-15T15:51:59+00:00April 15th, 2026|Endpoints News|
Updated: FDA asks for data on Lilly’s Foundayo to assess heart, liver risksnews2026-04-14T17:50:20+00:00April 14th, 2026|Endpoints News|
Parker Institute doubles down on cancer vaccines as part of ongoing rebootnews2026-04-14T11:00:49+00:00April 14th, 2026|Endpoints News|
Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promisenews2026-04-13T15:25:50+00:00April 13th, 2026|Endpoints News|
BioNTech’s HER2 ADC succeeds in Phase 2 study, FDA filing plannednews2026-04-13T14:32:17+00:00April 13th, 2026|Endpoints News|
Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3news2026-04-13T12:00:21+00:00April 13th, 2026|Endpoints News|
Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trialnews2026-04-13T10:51:33+00:00April 13th, 2026|Endpoints News|
